Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 2/20 | 0.32 |
| ▸ | TDP2 | O95551 | 2/20 | 0.32 |
| ▸ | NSD2 | O96028 | 2/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL15269829 | 0.98 | DNMT1 (0.37) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL4608905 | 0.88 | DNMT1 (0.43) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL249462 | 0.87 | DNMT1 (0.36) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL2951599 | 0.87 | MAPT (0.39) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL6176213 | 0.85 | CA1 (0.41) | DNMT1 | |
| Triaziquone SCHEMBL6009839 | 0.84 | DNMT1 (0.34) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL16419 | 0.84 | MAPT (0.42) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL8507558 | 0.84 | DNMT1 (0.41) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL11422311 | 0.84 | MAPT (0.42) | DNMT1MAPTHTTTP53STAT3 | |
| Triaziquone SCHEMBL6252286 | 0.84 | MAPT (0.37) | DNMT1MAPTHTTTP53STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114122259-A | Perovskite thin-film solar cell and preparation method thereof | 杭州纤纳光电科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | claimed |
| JP-4648630-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| EP-1513531-B1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | MENARINI RICERCHE SPA (IT) | 2009-10-21 | — | — | EP | claimed |
| JP-2005530711-A | — | — | 2005-10-13 | — | — | JP | claimed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| EP-0821674-B1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2003-08-06 | — | — | EP | claimed |
| US-20020045574-A1 | Glycopeptide antibacterial compounds and methods of using same | PRINCETON UNIVERSITY | 2002-04-18 | — | — | US | claimed |
| WO-2001081373-A2 | GLYCOPEPTIDE ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME | MERCK & CO., INC. (US) | 2001-11-01 | — | — | WO | claimed |
| EP-0821674-A1 | CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-02-04 | — | — | EP | claimed |
| EP-0468998-A1 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1992-02-05 | — | — | EP | claimed |
| WO-1990012804-A2 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1990-11-01 | — | — | WO | claimed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118317954-A | Indoline as PROTAC compound | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118251391-A | Benzimidazole carboxylic acids as GLP-1R agonists | 拓臻制药公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-0259417-A1 | RUTHENIUM CATALYST FOR BIARYLIC COUPLING; NEW STEGANOLIDES. | UNIV MAINE LE MANS (FR) | 1988-03-16 | — | — | EP | disclosed |
| EP-0239362-A2 | Anti-tumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987005289-A1 | RUTHENIUM CATALYST FOR BIARYLIC COUPLING; NEW STEGANOLIDES | UNIVERSITE DU MAINE (LE MANS) (FR) | 1987-09-11 | — | — | WO | disclosed |
| US-4460503-A | OLIGO AND POLYPEPTIDES | INSTITUT PASTEUR (FR) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045574-A1 | Glycopeptide antibacterial compounds and methods of using same | FUT6, DAO, B3GAT3 | DNMT1 3886/4885MAPT 4812/4885HTT 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.